The ADMET Bottleneck: Profiling Drug-Like Properties Before Synthesis

Most drug candidates fail not because they don't bind the target, but because they fail somewhere else: too insoluble to absorb, too toxic to tolerate, metabolized too quickly to maintain therapeutic concentration, or blocking a cardiac ion channel at clinically relevant exposures. ADMET profiling — absorption, distribution, metabolism, excretion, and toxicity — is where the majority of attrition happens. It is also where the majority of value is created in lead optimization.

What ADMET Actually Measures

ADMET encompasses a wide range of physicochemical, pharmacokinetic, and toxicological properties. Absorption depends on aqueous solubility, passive membrane permeability, and active transporter interactions. Distribution is governed by plasma protein binding, volume of distribution, and for CNS targets, blood-brain barrier penetration. Metabolism involves the cytochrome P450 enzyme family, which both inactivates drugs and generates reactive metabolites. Excretion depends on renal clearance and transporter-mediated biliary elimination. Toxicity includes direct mechanisms — hERG cardiac channel inhibition, mitochondrial dysfunction, reactive metabolite formation — and indirect mechanisms like drug-drug interactions from enzyme induction or inhibition.

BioMate evaluates all of these computationally, using models trained on large curated datasets of experimentally measured properties. For each compound, the platform generates a structured ADMET profile with predictions, confidence intervals where available, and comparisons to the literature-derived thresholds for the relevant therapeutic area and route of administration.

The Multi-Property Optimization Challenge

The core difficulty of lead optimization is that improving one property often degrades another. Adding a polar group improves solubility but may reduce membrane permeability. Increasing lipophilicity improves CNS penetration but raises hERG liability and metabolic instability. No single structural change optimizes all properties simultaneously.

BioMate approaches this as a multi-objective optimization problem. Molecular dynamics simulation provides a physics-based view of binding stability and selectivity that complements the computational ADMET predictions. Generative molecular design then explores structural variants, guided by a composite scoring function that weights all the target properties simultaneously — generating candidates that improve the weakest properties while maintaining the strengths of the current lead.

"The Design-Make-Test-Analyze loop is the engine of lead optimization. BioMate closes the Design and Analyze steps in silico — so wet-lab synthesis and assay time is spent on compounds already pre-filtered for the full property profile."

CYP450 Drug Interaction Panel

Drug-drug interactions mediated by cytochrome P450 enzymes are a major cause of clinical trial failure and post-market withdrawals. BioMate's CYP DDI panel evaluates inhibition and induction for the major CYP isoforms — 3A4, 2D6, 2C9, 2C19, 1A2 — and predicts the clinical drug interaction risk using regulatory-relevant metrics. Compounds that exceed risk thresholds are flagged early in the optimization process, while there is still structural flexibility to address the liability.

Further reading: ChEMBL bioactivity database (EBI), SwissADME (Swiss Institute of Bioinformatics), FDA novel drug approvals database, and RDKit cheminformatics toolkit.